Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 2Q 2025

Dallas, Texas–(Newsfile Corp. – February 18, 2025) – Incannex Healthcare Inc. (NASDAQ: IXHL): Stonegate Capital Partners updates their coverage on Incannex Healthcare Inc. (NASDAQ: IXHL). During the second quarter of fiscal year 2025, Incannex Healthcare Inc. reported R&D costs of $1.4M, a decrease from $2.6M in the same period of the previous year. This reduction was primarily due to the completion of the IHL-42X safety and pharmacokinetics clinical trial and the reallocation of resources from the Phase 2 IHL-675A Australia study to a larger U.S. Phase 2 study. The Company recovered 68.3% of these costs with an R&D tax incentive of $0.956 million. The net loss for the quarter was $5.9M, compared to $5.2M in the same period of the previous year.

To view the full announcement, including downloadable images, bios, and more, click here.

Key Takeaways:

• Incannex secured a strategic financing agreement with Arena Investors, which includes a $50M ELOC with Arena Business Solutions.
• IHL-42X had positive top-line results from a pharmacokinetics(PK) and safety study. The study demonstrated the bioavailability of IHL-42X, confirming the delivery of both drug components.
• When we use a probability adjusted DCF model, it returns an estimated share valuation range of $5.08 to $5.96 with a midpoint of $5.50.

Click image above to view full announcement.

About Stonegate

Stonegate Capital Partners is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies. Our affiliate, Stonegate Capital Markets (member FINRA) provides a full spectrum of investment banking services for public and private companies.

Source: Stonegate, Inc.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/241380

View more news from Reportable, Inc.

You are receiving this email because you have previously indicated your interest in receiving news for Reportable, Inc.

If you no longer want to receive messages from us, you can click here to unsubscribe.

Anti-Spam Policy | Privacy Policy